Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment With HPN-100, in Pediatric Subjects Under 6 Years of Age With Urea Cycle Disorders (UCDs)

NCT01347073 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01347073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01347073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment With HPN-100, in Pediatric Subjects Under 6 Years of Age With Urea Cycle Disorders (UCDs)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2011
Completion date
March 31, 2013
Enrollment
23 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

urea cycle disorders